Home » Pipeline
|optical coherence tomography (OTC)
|high-risk, complex coronary artery disease
|Phase I trials initiated enrolling 3,650 subjects in North America, Europe and Asia
|first-in-human clinical trial in patients with cystic fibrosis
|Phase I/II clearance given by the FDA
|Phase II results announced
|post-menopausal stress urinary incontinence (SUI)
|Phase II trials initiated enrolling 493 subjects at over 60 clinical trial centers across the U.S.
|BiondVax Pharmaceuticals Ltd.
|universal flu vaccine
|Phase II trials initiated enrolling 9,630 subjects age 50 years and older across four-to-six countries over a period of two flu seasons
|adult subjects with Tourette syndrome
|Phase IIa topline results announced
|moderate to severe Rheumatoid Arthritis
|Phase III topline results announced evaluating 37 subjects
|Orphan Drug Designation granted
|Clovis Oncology Inc.
|Rubraca (rucaparib) tablets
|adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy
|FDA approval granted
Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials
Learn More Here